Sign up to save your podcasts
Or
Share NADIM II & Favorable Risk RCC
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
NADIM II & Favorable Risk RCC
This episode...
More evidence to support the use of neoadjuvant ICI/chemo in stage III NSCLC to obtain pCR published this week with NADIM II.
Time to rethink giving ICI/TKI combination therapy to favorable-risk metastatic RCC patients? (Finally, I'm not the only one saying this anymore.)
NADIM II: https://www.nejm.org/doi/full/10.1056/NEJMoa2215530
FDA Pooled Analysis Favorable Risk metastatic RCC: https://doi.org/10.1016/j.eururo.2023.05.030
View all episodes
By John Bossaer
4.9
179179 ratings
This episode...
More evidence to support the use of neoadjuvant ICI/chemo in stage III NSCLC to obtain pCR published this week with NADIM II.
Time to rethink giving ICI/TKI combination therapy to favorable-risk metastatic RCC patients? (Finally, I'm not the only one saying this anymore.)
NADIM II: https://www.nejm.org/doi/full/10.1056/NEJMoa2215530
FDA Pooled Analysis Favorable Risk metastatic RCC: https://doi.org/10.1016/j.eururo.2023.05.030
More shows like OncoPharm
View all
JAMA Editors' Summary
127 Listeners
NEJM This Week
314 Listeners
JAMA Clinical Reviews
477 Listeners
The Curbsiders Internal Medicine Podcast
3,328 Listeners
Up First from NPR
56,161 Listeners
Core IM | Internal Medicine Podcast
1,086 Listeners
The ONS Podcast
197 Listeners
ASCO Guidelines
44 Listeners
Real Life Pharmacology - Pharmacology Education for Health Care Professionals
693 Listeners
OncLive® On Air
21 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
319 Listeners
The Curious Clinicians
364 Listeners
WolverHeme Happy Hour
28 Listeners
Two Onc Docs
166 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
37 Listeners